Anti-infectives are among the "Most Wanted" on the FDA short supply list, along with injectables for oncology, anesthesia/analgesics and critical care products. At latest count, 11 bacterial infection drugs are experiencing shortages.
One bright spot: APP Pharmaceuticals is giving its Grand Island, NY, manufacturing facility a $38 million makeover. The plant produces some drugs on the Most Wanted list: injectables for oncology and anti-infectives, in addition to anesthesia/analgesic and critical care products. But completion of the plant is likely to take until 2013.
Another bright spot: the FDA's approval in May of Optimer Pharmaceuticals' Dificid (fidaxomicin), for the treatment of Clostridium difficile--associated diarrhea in adults.
- Amikacin Injection; Bedford, Hospira, Teva
- Ampicillin Sulbactam; Hospira, Sandoz, Pfizer
- Azithromycin Injection; Apotex, Baxter, Teva, Pfizer
- Clarithromycin IR Tablets; Apotex, Mylan, Sandoz, Ranbaxy, Teva, UDL, Wockhardt, Abbott
- Ciprofloxacin Injection; Claris, Bedford, Teva, Merck, Bayer, Sandoz
- Ciprofloxacin IR Tablets; Scherling, Apotex, Cartlsbad, Major, Marlex, Ranbaxy, Teva, UDL
- Kanamycin Sulfate Injection; APP
- Dipyridamole Injection; Bedford, Teva
- Doxycycline Hyclate Injection; Bedford